Cited by 144Fatty Acid Research and HealthEicosanoids and Hypertension PharmacologyAtherosclerosis and Cardiovascular Diseases

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling

Open access

Elajami, Tarec K., Colas, Romain A., Dalli, Jesmond, Chiang, Nan, Serhan, Charles N., Welty, Francine K.·2016·The FASEB Journal

DOI 10.1096/fj.201500155rPMC PMC4970606

Open this paper in CoChat — free account

Abstract

Inflammation in arterial walls leads to coronary artery disease (CAD). Because specialized proresolving lipid mediators (SPMs; lipoxins, resolvins, and protectins) stimulate resolution of inflammation in animal models, we tested whether n‐3 fatty acids impact SPM profiles in patients with CAD and promote clot remodeling. Six patients with stable CAD were randomly assigned to either treatment with daily 3.36 g Lovaza for 1 yr or without. Targeted lipid mediator‐metabololipidomics showed that both groups had absence of resolvin D1 (RvD1), RvD2, RvD3, RvD5 and resolvin E1—all of which are present in healthy patients. Those not taking Lovaza had an absence of aspirin‐triggered resolvin D3 (AT‐RvD3) and aspirin‐triggered lipoxin B 4 (AT‐LXB 4 ). Lovaza treatment restored AT‐RvD3 and AT‐LXB 4 and gave levels of RvD6 and aspirin‐triggered protectin D1 (AT‐PD1) twice as high (resolvin E2 ~5 fold) as well as lower prostaglandins. Principal component analysis indicated positive relationships for patients with CAD who were receiving Lovaza with increased AT‐RvD3, RvD6, AT‐PD1, and AT‐LXB4.SPMs identified in Lovaza‐treated patients with CAD enhanced ~50% at 1 nM macrophage uptake of blood clots. These results indicate that patients with CAD have lower levels and/or absence of specific SPMs that were restored with Lovaza; these SPMs promote macrophage phagocytosis of blood clots. Together, they suggest that low vascular SPMs may enable progression of chronic vascular inflammation predisposing to coronary atherosclerosis and to thrombosis.—Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., Welty, F. K. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 30, 2792‐2801 (2016). www.fasebj.org

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1096/fj.201500155r

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial
(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Self-citation
n−3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases
Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1505s · Cited by 2,525
Untitled work
(1999) · PubMed · Cited by 2,062
The Human Serum Metabolome
Psychogios, N., Hau, D., Peng, J., Guo, A. C., Mandal, R., Bouatra, S., Sinelnikov, I. V., Krishnamurthy, R., Eisner, R., Gautam, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016957 · Cited by 1,779
Robbins and Cotran Pathologic Basis of Disease
Hoda, S. A., & Hoda, R. S. (2005) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000155072.86944.7d · Cited by 1,566
Lipid mediator class switching during acute inflammation: signals in resolution
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001) · Nature Immunology · doi:10.1038/89759 · Cited by 1,453
Self-citation
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929

Show all 51 references

Sorted by citations

Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341
Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators
Serhan, C. N., & Levy, B. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97943 · Cited by 1,344
Self-citation
Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms
Serhan, C. N. (2017) · The FASEB Journal · doi:10.1096/fj.201601222r · Cited by 566
Self-citation
An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques
Fredman, G., Hellmann, J., Proto, J. D., Kuriakose, G., Colas, R. A., Dorweiler, B., Connolly, E. S., Solomon, R., Jones, D. M., Heyer, E. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms12859 · Cited by 411
Self-citation
Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors
Chiang, N., & Serhan, C. N. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.03.005 · Cited by 338
Self-citation
Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis
Yurdagul, A., Doran, A. C., Cai, B., Fredman, G., & Tabas, I. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00086 · Cited by 300
Resolvins suppress tumor growth and enhance cancer therapy
Sulciner, M. L., Serhan, C. N., Gilligan, M. M., Mudge, D. K., Chang, J., Gartung, A., Lehner, K. A., Bielenberg, D. R., Schmidt, B. A. R., Dalli, J., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20170681 · Cited by 267
Self-citation
Arachidonic acid and other unsaturated fatty acids and some of their metabolites function as endogenous antimicrobial molecules: A review
Das, U. N. (2018) · Journal of Advanced Research · doi:10.1016/j.jare.2018.01.001 · Cited by 256
New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration
Serhan, C. N., Chiang, N., & Dalli, J. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.08.002 · Cited by 253
Self-citation
Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology
Sansbury, B. E., & Spite, M. R. (2016) · Circulation Research · doi:10.1161/circresaha.116.307308 · Cited by 238
Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis
Moore, K. J., Koplev, S., Fisher, E. A. A., Tabas, I. A., Björkegren, J., Doran, A. C., & Kovacic, J. C. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.2147 · Cited by 229
Inflammation and resolution in obesity
Soták, M., Clark, M., Suur, B. E., & Börgeson, E. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01047-y · Cited by 260
Carcinogenesis: Failure of resolution of inflammation?
Fishbein, A., Hammock, B. D., Serhan, C. N., & Panigrahy, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107670 · Cited by 218
Self-citation
The role of efferocytosis‐fueled macrophage metabolism in the resolution of inflammation
Schilperoort, M., Ngai, D., Sukka, S. R., Avrampou, K., Shi, H., & Tabas, I. A. (2023) · Immunological Reviews · doi:10.1111/imr.13214 · Cited by 184
Boosting Inflammation Resolution in Atherosclerosis
Fredman, G., & Tabas, I. A. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.018 · Cited by 179
Inflammation Resolution: Implications for Atherosclerosis
Doran, A. C. (2022) · Circulation Research · doi:10.1161/circresaha.121.319822 · Cited by 181
Dietary fats and cardiometabolic disease: mechanisms and effects on risk factors and outcomes
Wu, J. H. Y., Micha, R., & Mozaffarian, D. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0206-1 · Cited by 172
Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease
Fredman, G., & Serhan, C. N. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00984-x · Cited by 176
Self-citation
Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: Concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake
Calder, P. C. (2020) · Biochimie · doi:10.1016/j.biochi.2020.08.015 · Cited by 155
Polyunsaturated Fatty Acids: Conversion to Lipid Mediators, Roles in Inflammatory Diseases and Dietary Sources
Harwood, J. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108838 · Cited by 147
Δ-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators
Gromovsky, A. D., Schugar, R. C., Brown, A. L., Helsley, R. N., Burrows, A. C., Ferguson, D., Zhang, R., Sansbury, B. E., Lee, R. G., Morton, R. E., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309660 · Cited by 115
Narrative Review of n-3 Polyunsaturated Fatty Acid Supplementation upon Immune Functions, Resolution Molecules and Lipid Peroxidation
Zaloga, G. P. (2021) · Nutrients · doi:10.3390/nu13020662 · Cited by 113
Specialized pro-resolving mediators in cardiovascular diseases
Fredman, G., & Spite, M. R. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.02.003 · Cited by 103
Resolvin D4 attenuates the severity of pathological thrombosis in mice
Cherpokova, D., Jouvene, C. C., Libreros, S., DeRoo, E., Chu, L., de la Rosa, X., Norris, P. C., Wagner, D. D., & Serhan, C. N. (2019) · Blood · doi:10.1182/blood.2018886317 · Cited by 98
Self-citation
Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial
Alfaddagh, A., Elajami, T. K., Ashfaque, H., Saleh, M. A., Bistrian, B. R., & Welty, F. K. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006981 · Cited by 96
Self-citation
Targeting immune cell recruitment in atherosclerosis
Döring, Y., van der Vorst, E. P. C., & Weber, C. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01023-z · Cited by 99
The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification
Carracedo, M., Artiach, G., Arnardottir, H. H., & Bäck, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00767-y · Cited by 100
Pro-resolving lipid mediators in vascular disease
Conte, M. S., Desai, T. A., Wu, B., Schaller, M. S., & Werlin, E. C. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97947 · Cited by 82
Specialized pro-resolving lipid mediators: A new class of non-immunosuppressive and non-opioid analgesic drugs
Fattori, V., Zaninelli, T. H., Rasquel-Oliveira, F. S., Casagrande, R., & Verri, W. A., Jr. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104549 · Cited by 81
Pneumonia-Induced Inflammation, Resolution and Cardiovascular Disease: Causes, Consequences and Clinical Opportunities
Stotts, C., Corrales‐Medina, V., & Rayner, K. J. (2023) · Circulation Research · doi:10.1161/circresaha.122.321636 · Cited by 89
Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial
Arnardottir, H. H., Pawelzik, S., Öhlund‐Wistbacka, U., Artiach, G., Hofmann, R., Reinholdsson, I., Braunschweig, F., Tornvall, P., Religa, D., & Bäck, M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.624657 · Cited by 75
A cluster of immunoresolvents links coagulation to innate host defense in human blood
Norris, P. C., Libreros, S., Chiang, N., & Serhan, C. N. (2017) · Science Signaling · doi:10.1126/scisignal.aan1471 · Cited by 68
Self-citation
Omega-3 Fatty Acids in Atherosclerosis and Coronary Artery Disease
Bäck, M. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0067 · Cited by 73
Omega 3 Fatty Acid and Skin Diseases
Sawada, Y., Saito‐Sasaki, N., & Nakamura, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.623052 · Cited by 68
Chronic Inflammation in PCOS: The Potential Benefits of Specialized Pro-Resolving Lipid Mediators (SPMs) in the Improvement of the Resolutive Response
Regidor, P., Mueller, A., Sailer, M., Santos, F. G., Rizo, J. M., & Egea, F. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010384 · Cited by 70
The great obstetrical syndromes and the placenta
Hoffman, M. (2023) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17613 · Cited by 72
Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications
Wu, B., Mottola, G., Schaller, M. S., Upchurch, G. R., & Conte, M. S. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.07.005 · Cited by 66
Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial)
Ramirez, J. L., Gasper, W. J., Khetani, S. A., Zahner, G. J., Hills, N. K., Mitchell, P. T., Sansbury, B. E., Conte, M. S., Spite, M. R., & Grenon, S. M. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.01.038 · Cited by 63
Regression of human coronary artery plaque is associated with a high ratio of (18‐hydroxy‐eicosapentaenoic acid + resolvin E1) to leukotriene B 4
Welty, F. K., Schulte, F., Alfaddagh, A., Elajami, T. K., Bistrian, B. R., & Hardt, M. (2021) · The FASEB Journal · doi:10.1096/fj.202002471r · Cited by 58
Self-citation
Atherosclerosis, Periodontal Disease, and Treatment with Resolvins
Hamilton, J. A., Hastürk, H., Kantarcı, A., Serhan, C. N., & Dyke, T. E. V. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0696-4 · Cited by 55
Self-citation
Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach
Cofer, L. B., Barrett, T. J., & Berger, J. S. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318020 · Cited by 58
Insights into the cardioprotective properties of n-3 PUFAs against ischemic heart disease via modulation of the innate immune system
Darwesh, A. M., Sosnowski, D. K., Lee, T. Y., Keshavarz-Bahaghighat, H., & Seubert, J. M. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.04.037 · Cited by 51
Effects of Aspirin on Endothelial Function and Hypertension
Dzeshka, M. S., Shantsila, A., & Lip, G. Y. H. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0688-8 · Cited by 47
The Role of Resolvins: EPA and DHA Derivatives Can Be Useful in the Prevention and Treatment of Ischemic Stroke
Tułowiecka, N., Kotlęga, D., Prowans, P., & Szczuko, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207628 · Cited by 45
Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension
del Campo, L. S. D., García‐Redondo, A. B., Rodrı́guez, C., Zaragoza, C., Duro‐Sánchez, S., Palmas, F., de Benito-Bueno, Á., Socuéllamos, P. G., Peraza, D. A., Rodrigues‐Díez, R., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19448 · Cited by 45
Self-citation
Modulation of innate immunity of patients with Alzheimer's disease by omega‐3 fatty acids
Fiala, M., Kooij, G., Wagner, K. M., Hammock, B. D., & Pellegrini, M. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700065r · Cited by 44
Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases
Perucci, L. O., Sugimoto, M. A., Gomes, K. B., Dusse, L. M. S., Teixeira, M. M., & Sousa, L. P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1364363 · Cited by 45
Lipoxin B4 Enhances Human Memory B Cell Antibody Production via Upregulating Cyclooxygenase-2 Expression
Kim, N., Lannan, K. L., Thatcher, T. H., Pollock, S. J., Woeller, C. F., & Phipps, R. P. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700503 · Cited by 42
Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition
Al‐Shaer, A. E., Buddenbaum, N., & Shaikh, S. R. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158936 · Cited by 47
Resolvins as proresolving inflammatory mediators in cardiovascular disease
Capó, X., Martorell, M., Busquets-Cortés, C., Tejada, S., Tur, J. A., Pons, A., & Sureda, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.018 · Cited by 46
Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction
Fosshaug, L. E., Colas, R. A., Anstensrud, A. K., Gregersen, I., Nymo, S. H., Sagen, E. L., Michelsen, A. E., Vinge, L. E., Øie, E., Gullestad, L. L., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.024 · Cited by 42
Self-citation
Novel RvD6 stereoisomer induces corneal nerve regeneration and wound healing post-injury by modulating trigeminal transcriptomic signature
Pham, T. L., Kakazu, A. H., He, J., Jun, B., Bazan, N. G., & Bazán, H. E. P. (2020) · Scientific Reports · doi:10.1038/s41598-020-61390-8 · Cited by 42
Roles of Resolvins in Chronic Inflammatory Response
Liu, C., Fan, D., Lei, Q., Lü, A., & He, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314883 · Cited by 42
Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway
Mottola, G., Chatterjee, A., Wu, B., Chen, M., & Conte, M. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174936 · Cited by 41
Omega‐3 fatty acids in coronary heart disease: Recent updates and future perspectives
Ajith, T. A., & Jayakumar, T. G. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13034 · Cited by 43
Function of Pro-Resolving Lipid Mediator Resolvin E1 in Type 2 Diabetes
Sima, C., Paster, B. J., & Dyke, T. E. V. (2018) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2018026750 · Cited by 41
Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy
Kim, A. S., & Conte, M. S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.011 · Cited by 42
Early evidence of efficacy for orally administered SPM-enriched marine lipid fraction on quality of life and pain in a sample of adults with chronic pain
Callan, N. G. L., Hanes, D., & Bradley, R. D. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02569-5 · Cited by 42
Atherothrombosis and the NLRP3 inflammasome – endogenous mechanisms of inhibition
Satish, M., & Agrawal, D. K. (2019) · Translational research · doi:10.1016/j.trsl.2019.08.003 · Cited by 39
The effect of polyunsaturated fatty acids on the severity and mortality of COVID patients: A systematic review
Mazidimoradi, A., Alemzadeh, E., Alemzadeh, E., & Salehiniya, H. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120489 · Cited by 39
Aspirin Triggered Resolvin D1 reduces inflammation and restores saliva secretion in a Sjögren’s syndrome mouse model
Dean, S. M., Wang, C., Nam, K., Maruyama, C. L., Trump, B., & Baker, O. J. (2019) · Rheumatology · doi:10.1093/rheumatology/kez072 · Cited by 36
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis
Bäck, M. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108439 · Cited by 35
Specialized pro‐resolving mediators enhance the clearance of dead cells
Fredman, G., & Khan, S. (2023) · Immunological Reviews · doi:10.1111/imr.13278 · Cited by 35
Deep Airway Inflammation and Respiratory Disorders in Nanocomposite Workers
Pelclová, D., Ždı́mal, V., Komarc, M., Vlčková, Š., Fenclová, Z., Ondráček, J., Schwarz, J., Koštejn, M., Kačer, P., Dvorackova, S., et al. (2018) · Nanomaterials · doi:10.3390/nano8090731 · Cited by 35
Specialized Pro-Resolving Lipid Mediators: New Therapeutic Approaches for Vascular Remodeling
del Campo, L. S. D., Rodrigues‐Díez, R., Salaíces, M., Briones, A. M., & García‐Redondo, A. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073592 · Cited by 36
Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19
Regidor, P., Santos, F. G., Rizo, J. M., & Egea, F. M. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110340 · Cited by 35
Immunomodulation by intravenous omega‐3 fatty acid treatment in older subjects hospitalized for COVID‐19: A single‐blind randomized controlled trial
Arnardottir, H. H., Pawelzik, S., Sarajlic, P., Quaranta, A., Kolmert, J., Religa, D., Wheelock, C. E., & Bäck, M. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.895 · Cited by 33
Variability in the Clinical Effects of the Omega-3 Polyunsaturated Fatty Acids DHA and EPA in Cardiovascular Disease—Possible Causes and Future Considerations
Michaeloudes, C., Christodoulides, S., Christodoulou, P., Kyriakou, T.-C., Patrikios, I. S., & Stephanou, A. (2023) · Nutrients · doi:10.3390/nu15224830 · Cited by 38
Pro-Resolving Ligands Orchestrate Phagocytosis
Decker, C., Sadhu, S., & Fredman, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660865 · Cited by 34
Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis
Lubrano, V., Ndreu, R., & Balzan, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021637 · Cited by 33
Specialized Pro-Resolving Mediators as Potential Regulators of Inflammatory Macrophage Responses in COVID-19
Balta, M. G., Papathanasiou, E., & CHRISTOPOULOS, P. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632238 · Cited by 28
Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis
Kraft, J. D., Blomgran, R., Bergström, I., Soták, M., Clark, M., Rani, A., Rajan, M. R., Dalli, J., Nyström, S., Quiding‐Järbrink, M., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202101219rr · Cited by 29
Self-citation
Rapid Metabolization of Protectin D1 by β-Oxidation of Its Polar Head Chain
Balas, L., Risé, P., Dayaker, G., Rovati, G. E., Bolego, C., Stellari, F. F., Trenti, A., Buccellati, C., Durand, T., & Sala, A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01463 · Cited by 27
Dietary Control of Inflammation and Resolution
Sears, B., & Saha, A. K. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.709435 · Cited by 30
Specialized pro-resolving mediators in diabetes: novel therapeutic strategies
Brennan, E. P., Mohan, M., Andrews, D. C., Bose, M., & Kantharidis, P. (2019) · Clinical Science · doi:10.1042/cs20190067 · Cited by 30
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis
Salazar, J. J., Pírela, D., Nava, M., Castro, A. V., Angarita, L., Parra, H., Durán‐Agüero, S., Rojas-Gómez, D. M., Galbán, N., Áñez, R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063133 · Cited by 26
Aspirin modulates production of pro-inflammatory and pro-resolving mediators in endothelial cells
Rood, K. M., Patel, N., DeVengencie, I., Quinn, J. P., Gowdy, K. M., Costantine, M. M., & Kniss, D. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283163 · Cited by 25
The role of Resolvin D1 in liver diseases
Yang, M., Song, X.-Q., Han, M., & Liu, H. (2022) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2022.106634 · Cited by 25
Arachidonic Acid and Docosahexaenoic Acid Metabolites in the Airways of Adults With Cystic Fibrosis: Effect of Docosahexaenoic Acid Supplementation
Teopompi, E., Risé, P., Pisi, R., Buccellati, C., Aiello, M., Pisi, G., Tripodi, M. C., Fainardi, V., Clini, E. M., Chetta, A. A., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00938 · Cited by 25
Can Inflammation-Resolution Provide Clues to Treat Patients According to Their Plaque Phenotype?
Fredman, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00205 · Cited by 22
Specialized Pro-resolving Mediators Directs Cardiac Healing and Repair with Activation of Inflammation and Resolution Program in Heart Failure
Halade, G. V., & Tourki, B. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-21735-8_6 · Cited by 21
Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil?
Rosenthal, M. D., Patel, J. J., Staton, K. M., Martindale, R. G., Moore, F. A., & Upchurch, G. R. (2018) · Current Gastroenterology Reports · doi:10.1007/s11894-018-0647-4 · Cited by 20
The Role of Serum Resolvin D1 Levels in Determining the Presence and Prognosis of ST-Segment Elevation Myocardial Infarction
Karayiğit, O., Nurkoç, S. G., Başyiğit, F., & Kızıltunç, E. (2022) · Medical Principles and Practice · doi:10.1159/000527064 · Cited by 20
Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion
Duchez, A., Fauteux‐Daniel, S., Sut, C., Ebermeyer, T., Heestermans, M., Arthaud, C., Eyraud, M., Prier, A., Audoux, E., Bertrand‐Michel, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1031968 · Cited by 18
Angiopoietin-like protein 3, an emerging cardiometabolic therapy target with systemic and cell-autonomous functions
Ruhanen, H., Haridas, P. A. N., Jauhiainen, M., & Olkkonen, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158791 · Cited by 18
Specialized Pro‐Resolving Mediators as Emerging Players in Cardioprotection: From Inflammation Resolution to Therapeutic Potential
Bartolo, A. D., Romeo, N., Angelone, T., & Rocca, C. (2025) · Acta Physiologica · doi:10.1111/apha.70062 · Cited by 16
Pro-resolving lipid mediators in diseases: exploring the molecular basis and clinical implication
Li, C., Wang, Z., Yang, Y., Jiang, Q., Jiang, Y., Xiao, J., Shen, L., Wu, W., & Li, C. (2026) · Molecular Biomedicine · doi:10.1186/s43556-025-00400-5 · Cited by 22
ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins
Ruhanen, H., Haridas, P. A. N., Minicocci, I., Taskinen, J., Palmas, F., Costanzo, A. D., D’Erasmo, L., Metso, J., Partanen, J., Dalli, J., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158679 · Cited by 16
Self-citation
Development and Validation of Methodologies for the Identification of Specialized Pro-Resolving Lipid Mediators and Classic Eicosanoids in Biological Matrices
Dooley, M., Saliani, A., & Dalli, J. (2024) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.4c00211 · Cited by 15
Self-citation
Pro-resolving lipid mediators in the resolution of neointimal hyperplasia pathogenesis in atherosclerotic diseases
Satish, M., & Agrawal, D. K. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1563483 · Cited by 15
Receptors for pro-resolving mediators as a therapeutic tool for smooth muscle remodeling-associated disorders
Livshits, G., & Kalinkovich, A. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105340 · Cited by 16
DHA, RvD1, RvD5, and MaR1 reduce human coronary arteries contractions induced by PGE2
Bouhadoun, A., Manikpurage, H. D., Deschildre, C., Zalghout, S., Dubourdeau, M., Urbach, V., Ho‐Tin‐Noé, B., Deschamps, L., Michel, J., Longrois, D., et al. (2022) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2022.106700 · Cited by 13
Lipoxins and their relationship with inflammation-associated diseases. A systematic review
Serna-Orozco, M. F., Mosquera, M., & García‐Perdomo, H. A. (2023) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2023.06.001 · Cited by 13
Oral Resolvin D1 attenuates early inflammation but not intimal hyperplasia in a rat carotid angioplasty model
Mottola, G., Werlin, E. C., Wu, B., Chen, M., Chatterjee, A., Schaller, M. S., & Conte, M. S. (2019) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2019.106401 · Cited by 13
Integrated metabolomics, network pharmacology and biological verification to reveal the mechanisms of Nauclea officinalis treatment of LPS-induced acute lung injury
Han, X., Xu, S., Li, L., Wu, Y., Mai, S.-Y., Xie, Y., Tan, Y., Li, A., Xue, F., He, X., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00685-6 · Cited by 12
Dietary Technologies to Optimize Healing from Injury-Induced Inflammation
Sears, B., Perry, M., & Saha, A. K. (2020) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523019666200512114210 · Cited by 13
COVID-19 and cancer: start the resolution!
Barksdale, C., Kipper, F. C., Tripathy, S., Subbian, S., Serhan, C. N., & Panigrahy, D. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10017-z · Cited by 14
Self-citation
Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers
Offman, E. M., Davidson, M. H., Abu-Rashid, M., Chai, P., & Nilsson, C. A. M. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-016-0398-2 · Cited by 14
Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS)
Aznar, A. G., Egea, F. M., Banzo, R. G., Gutiérrez, R., Rizo, J. M., Ledo, P. R., Nerín, I., & Regidor, P. (2024) · Biomedicines · doi:10.3390/biomedicines12102221 · Cited by 10
Resolvin D1 attenuates Ang II-induced hypertension in mice by inhibiting the proliferation, migration and phenotypic transformation of vascular smooth muscle cells by blocking the RhoA/mitogen-activated protein kinase pathway
Cheng, W., Zhang, J., Peng, S., Liu, J., Xu, Y. Q., Zhao, M., Xu, S., Pan, W. D., Yin, Z., Zheng, Z., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003610 · Cited by 10

Authors: Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., & Welty, F. K.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Welty, Francine K.
ORCID: Elajami, Tarec K.
Dalli, Jesmond
Chiang, Nan
Serhan, Charles N.
Welty, Francine K.
Venue: The FASEB Journal
Publisher: Wiley
Published: 2016-04-27
Volume: 30
Issue: 8
Pages: 2792-2801
ISSN: 0892-6638 (ISSN-L)
1530-6860
DOI: 10.1096/fj.201500155r
PMC: PMC4970606
OpenAlex: W2344216384
Cited by: 143
References: 51
Citations by year: 2026: 8 · 2025: 5 · 2024: 11 · 2023: 17 · 2022: 23 · 2021: 10 · 2020: 15 · 2019: 19 · 2018: 13 · 2017: 17 · 2016: 5
FWCI: 18.84
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: The FASEB Journal (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (P01GM095467, RO1GM03865, P50HL083813)
Topics: Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords: coronary artery disease, omega-3 fatty acids, lipoxin B4, protectin D1, vascular inflammation, thrombosis, atherosclerosis
MeSH terms: Aged, Aspirin, Coronary Disease, Docosahexaenoic Acids, Drug Combinations, Female, Gene Expression Regulation, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Eicosapentaenoic Acid, Biomarkers, Fatty Acids, Omega-3, Lipoxins, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks